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Abstract: 
It might be possible to treat genetic skin diseases by correcting defective RNA. In this issue 
of Experimental Dermatology, Bornert et al review the latest developments in this area. 
Progress is rapid and impressive. Clinical use of RNA correction looks set to soon become 
reality. The future looks bright indeed. But, as always, we have to think before we act. In my 
comment, I provide a much-needed reality check. 
 
 
For the vast majority of genetic skin disorders there is no specific treatment. Our 
understanding of their biology, mildly put, is still limited. As a result, small molecule 
approaches are not a viable option right now. There are a few notable exceptions, such as 
tuberous sclerosis (1). 
 
However, the gene defects underlying most genodermatoses are now known. One could 
therefore consider dispensing with all that complicated biology. Instead, one might attempt 
to correct or replace the faulty gene, or supply its product. Unfortunately, most such 
approaches don’t work. For genetic skin disorders, they haven’t even been tried. Some 
groups have tried to treat recessive dystrophic epidermolysis bullosa (RDEB) with allogeneic 
bone marrow transplantation or mesenchymal stem cells (2). Transient symptom relief was 
reported with both modalities. Yet, there is no convincing proof of efficacy beyond a 
placebo effect as it is not possible right now to objectively measure how severe RDEB is. 
Also, allogeneic bone marrow transplantation is a risky procedure.  
Much work has been done on cell therapy. Here, the genetic defect is corrected in isolated 
patient keratinocytes that are then transplanted back onto affected skin. This approach has 
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yet to prove its merits in the clinic. Moreover, gene correction in most work published to 
date was achieved with retro- or lentiviruses. There are still significant safety issues 
surrounding the use of such viruses (3). CRISPR/Cas9 mediated gene editing is a recent 
development and holds great promise (4), but will take a long time to become useful as a 
therapy because of practical and ethical concerns. So it seems that our patients are still 
facing a bleak future.  
 
But there is hope. Treatment of genetic skin disorders could focus on (pre-)mRNA. Avoiding 
permanent alterations to the DNA – even when limited to stem cells – circumvents many 
ethical issues. One would also not have to deal with difficulties inherent in cell or protein 
replacement.  
 
Recent advances bring RNA-based therapies for genodermatoses closer to the clinic, but 
several challenges remain. As Bornert et al discuss in this issue of Experimental Dermatology 
(5), there are several ways to target (pre-)mRNA for therapeutic benefit. Antisense 
oligonucleotides (AON) or small interfering RNAs (siRNA) can reduce gene expression. siRNA 
has been tested with some success, in a patient with pachyonychia congenita (6).  
However, gene silencing has important disadvantages. The knockdown approach applies to 
dominant disorders only. Also, it is mutation-specific although in some cases one could 
target SNPs that are in phase with the mutation. That would make knockdown applicable to 
more patients, as long as they have the right SNP.  
Trans-splicing is a more exotic technique that is not mutation-specific (5). Here, a wild-type 
piece of RNA replaces the part of the endogenous pre-mRNA that contains the mutation. 
Finally, AON can modulate splicing so they could cause exons with a disease-causing 
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mutation to be skipped. This results in expression of a shorter protein. In some cases, 
enough functionality remains to treat the disease. This approach is being pursued for 
recessive dystrophic epidermolysis bullosa (7). 
 
Of course, all these methods need delivery of oligonucleotides to the target tissue. Upon 
systemic administration, these molecules accumulate in liver and kidney, not the skin (8). 
Tinkering with the backbone chemistry might help to achieve dermal delivery, but for many 
genodermatoses the epidermis must be targeted. So topical application seems to be the 
most appropriate approach. Since oligonucleotides are large molecules, that is going to be a 
tough challenge. Several methods to overcome this obstacle have been proposed and tried 
(9), so far without much success. A major effort in this area is necessary, if RNA-based 
treatments for genodermatoses are to work.  
 
Other obstacles remain and Bornert and colleagues discuss these, except for one that I 
already mentioned in the context of RDEB treatment. We need objective outcome measures 
for future clinical trials in genetic skin disease. This need is all the more pressing for rare 
disorders, where the number of patients to be treated will be low. Unfortunately, 
genodermatology does not seem to be in a hurry to develop outcome measures. This must 
change to make sure that people with a genetic skin disease can profit from the recent, 
dramatic advances in biology. Patient organisations, scientists and caregivers should 
therefore make developing objective outcome measures their number one priority. 
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